HomeVideoJosef Bodor | Institute of Hematology and Blood Transfusion | Czech Republic | Euro Cancer Summit 2015 | Conference Series LLC

Josef Bodor | Institute of Hematology and Blood Transfusion | Czech Republic | Euro Cancer Summit 2015 | Conference Series LLC



8th Euro Global Summit on Cancer Therapy November 03-05, 2015 Meliá Valencia, Valencia, Spain

Scientific Talk On: Hematopoietic stem cell-based therapy for HIV disease: Prostaglandinmodulated transplantation

Click here for Abstract and Biography: http://cancer.global-summit.com/europe/speaker/2015/josef-bodor-institute-of-hematology-and-blood-transfusion-czech-republic

Biography:

Josef Bodor received his Ph.D. (1990) with honors from Institute of Molecular Genetics in Prague, Czech Republic. As of 2013, he is a Senior Investigator working at the Instituternof Experimental Medicine in Prague, Czech Republic. Dr. Bodor is a senior scientist with faculty experience from Ivy League Institutions in US hosting on sabbatical leaves aroundrnthe world (Harvard University Boston, MA, Columbia University; New York, NY, Kyoto University, Kyoto, Japan, Würzburg University, Würzburg, Germany, and Johannes GutenbergrnUniversity in Mainz, Germany). Dr. Bodor as an Associate Member of Transregio 52 published series of original reports summarized in authoritative reviews. Currently, Dr. Bodor isrnfaculty member at the Institute of Hematology and Blood Transfusion in Prague, Czech Republic.

Abstract:

At present, the general consensus is that ‘true’ self-renewing human hematopoietic stem cells (HSCs) are found within the CD34+ populationrnand that engraft ment of a suitably conditioned host with a suffi cient number of such cells will result in long-term multilineage hematopoiesis.rnUmbilical Cord Blood (UCB) cells are a valuable source of HSCs for use in allogeneic transplantation. Key advantages are easy availability andrnless stringent requirements for HLA matching. However, UCB cells contain an inherently limited HSC count associated with delayed time ofrnengraft ment, high graft failure rates and early mortality. PGE2 derivative (16, 16 dimethylprostaglandin E2; dmPGE2) was recently identifi edrnto be a critical regulator of HSC homeostasis (1). Recent data have shown that brief ex vivo modulation with dmPGE2 could improve patientrnoutcomes by increasing the ‘eff ective dose’ of HSCs with preferential long-term engraft ment of the dmPGE2 treated HSCs in allogeneicrntransplantation. Moreover, it was demonstrated that conventional CD4+ T cells (Tcons) could be developed in vitro into CD4+CD25+Foxp3+rninducible regulatory T cells (iTregs) with an equivalent suppressive potential as naturally occuring regulatory T cells (nTregs) by continuousrnpolyclonal activation with anti-CD3/CD28 mAbs (2). During the diff erentiation process, the iTregs express cyclooxygenase 2 (COX-2) andrnproduce PGE2. Interestingly, neither resting nor activated nTregs express COX-2. Th e PGE2 production from iTregs can be fully suppressed byrnthe COX inhibitor indomethacin. Th ese data indicate that PGE2 plays an important role in diff erentiation of HSCs thus releasing stringencyrnrequired for HLAmatching donors with potential recipients as well as with potential role in dominant suppressive eff ects of iTregs expressingrnCOX-2 with acquired ability to produce copious amounts of PGE2 responsible for delivery of suppressive function through elevated levels ofrncAMP (3). Prostaglandin E2 (PGE2)-mediated mechanisms, which have potential to downregulate CCR5 expression in umbilical cord bloodrn(UCB) cells heterozygous for CCR5Δ32 mutation (CCR5wt/Δ32), could reduce or eliminate surface expression of CCR5 (CCR5 null cells)rnand thus facilitate allogeneic transplantation, UCB cell-engraft ment, and preferential cord chimerism in parallel with CCR5 downregulation.rnKey advantages of this process are higher frequency of heterozygous CCR5wt/Δ32 donors, less stringent requirements for HLA matching,rnand better engraft ment of the cells resistant to HIV. To eliminate the need for indefi nite treatment, our ultimate goal is to create a functionalrnHIVresistant immune system through the use of modifi ed HSCs with emphasis on post-transplant amelioration of GvHD enabled viarnpotentiation of regulatory T cell (Treg) cell-mediated suppression.

Conference Series LLC (3000+ Global Events): www.conferenceseries.com
Global Medical Conferences: www.conferenceseries.com
Global Nursing Conferences: www.nursingconference.com
Global Pharmaceutical Conferences: www.pharmaceuticalconferences.com
Global Cancer Conferences: www.cancersummit.org 
Global Diabetes Conferences: www.diabetesexpo.com 
Global Dental Conferences: www.dentalcongress.com 
700+ Open Access Journals: www.omicsonline.org 

Likes: 0

Viewed:

source

Previous post
Revertendo DIABETES - Reportagem Mostra Como Destruir a Diabetes Naturalmente
Next post
Spotlighting the NCD Problem

Leave a Reply

Be the First to Comment!

Notify of
avatar
wpDiscuz